Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma

Oncogene

Volumn 28, Issue 19, 2009, Pages 2024-2033

  Lau, L M S ^a,b,d   Wolter, J K ^b   Lau, J T M L ^b   Cheng, L S ^b   Smith, K M ^b   Hansford, L M ^b   Zhang, L ^b   Baruchel, S ^a,b   Robinson, F ^b   Irwin, M S ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Celecoxib; COX inhibitor; E2F 1; Neuroblastoma; P73

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; CELECOXIB; DICLOFENAC; DOXORUBICIN; INDOMETACIN; ISOPROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR E2F1; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSACTIVATION; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECT; GENETICS; METABOLISM; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; APOPTOSIS; CYCLOOXYGENASE INHIBITORS; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 66149120695     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.59     Document Type: Article

References (34)

1. Amin AR, Paul RK, Thakur VS, Agarwal ML. (2007). A novel role for p73 in the regulation of Akt-Foxola-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res 67: 5617-5621.
2. Balint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. (2002). Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA 99: 3529-3534.
3. Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE et al. (2007). Celecoxib toxicity is cell cycle phase specific. Cancer Res 67: 3801-3808.
4. Buhlmann S, Putzer BM. (2008). DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 1785: 207-216.
5. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G et al. (2002). Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251.
6. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R et al. (2005). Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11: 8372-8383.
7. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L et al. (2006). DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24: 805-815.
8. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E et al. (2001). Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20: 514-522.
9. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
10. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. (2005). p73beta-mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res 65: 2186-2192.
11. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. (2006). Cycloox-ygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747.
12. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS et al. (2007). Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 67: 11234-11243.
13. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W et al. (2000). Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648.
14. Irwin MS. (2004). Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle 3: 319-323.
15. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. (2003). Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410.
16. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A et al. (2004). Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64: 7210-7215.
17. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A et al. (2005). A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 105: 2504-2509.
18. Kashfi K, Rigas B. (2005). Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70: 969-986.
19. Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR et al. (2007). Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuro-blastoma. Oncogene 26: 1920-1931.
20. Lau LM, Nugent JK, Zhao X, Irwin MS. (2008). HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 27: 997-1003.
21. Maris JM, Hogarty MD, Bagatell R, Cohn SL. (2007). Neuroblasto-ma. Lancet 369: 2106-2120.
22. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H et al. (2005). TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12: 1564-1577.
23. Ponthan F, Wickstrom M, Gleissman H, Fuskevag OM, Segerstrom L, Sveinbjornsson B et al. (2007). Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13: 1036-1044.
24. Pozniak CD, RadinovicS, Yang A, McKeon F, Kaplan DR, Miller FD. (2000). An anti-apoptoticrole for the p53 family member, p73, during developmental neuron death. Science 289: 304-306.
25. Putzer BM. (2007). E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 11: 239-251.
26. Putzer BM, Tuve S, Tannapfel A, Stiewe T. (2003). Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript. Cell Death Differ 10: 612-614.
27. Sayan AE, Paradisi A, Vojtesek B, Knight RA, Melino G, Candi E. (2005). New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun 330: 186-193.
28. Stempak D, Gammon J, Klein J, Koren G, Baruchel S. (2002). Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 72: 490-497.
29. Stiewe T, Putzer BM. (2000). Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26: 464-469.
30. Stiewe T, Theseling CC, Putzer BM. (2002). Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277: 14177-14185.
31. Thun MJ, Henley SJ, Patrono C. (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266.
32. Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL et al. (2007). p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 67: 10351-10360.
33. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M et al. (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196: 765-780.
34. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW et al. (2004). From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64: 4309-4318.